News

Robert Ward appointed as Activation Capital’s interim president and chief executive officer

The Virginia Biotechnology Research Park Authority Board appointed Robert Ward as interim president and chief executive officer of Activation Capital, an innovation ecosystem development organization, effective today. Ward is a senior executive with over 25 years of experience leading organizations, driving strategy and innovation, developing high performing teams and executing complex transactions.

Ward has served as Virginia’s chief transformation officer where he supported agency secretaries with technologies to improve their operations. And prior to that, he was senior adviser to Gov. Glenn Youngkin.

“We are excited to welcome Rob Ward as interim CEO of Activation Capital,” said VCU President and Activation Capital board chair Michael Rao. “Rob brings extensive experience in corporate real estate and strategic development in his career at Skanska, a background that will help us advance Activation Capital’s mission and capital project priorities. As a Virginia Tech alumnus and Virginia resident, Rob understands Virginia and our strengths as an ideal location to grow pharmaceutical manufacturing and innovative biotechnology industries.”

Ward previously was the president and CEO for Skanska Commercial Development U.S., where he set the strategic direction of the company while driving continuous improvement through operational effectiveness, efficiency, and innovation. As CEO, he had responsibility for the investment, development, and construction of more than $4.5B of commercial and residential assets across the country.

Prior to becoming CEO, he served as the COO for the organization where he led the U.S. Investment Committee as well as the Strategic Services Team which included product innovation, technology, customer strategy, systems optimization, operational excellence, portfolio management and construction. Prior to his role as COO, Robert had direct oversight of offices/operations in the mid-Atlantic region, Houston, Texas and Los Angeles, California.

His career at Skanska began in the commercial construction division. He served on the executive leadership teams in both the mid-Atlantic and Southeast U.S. markets where he focused on life science, pharmaceutical, higher education, and federal government construction projects.

“I want to thank outgoing CEO Chandra Briggman for her leadership and I look forward to furthering Activation Capital’s mission and priorities as interim CEO,” Ward said. As the search continues for a CEO, I am committed to growing and fostering Activation Capital’s venture, ecosystem and pharmaceutical cluster development.”

Ward has served on real estate development and construction boards in the United States, Central Europe, the Nordics and the United Kingdom.

Ward is a graduate of Virginia Tech and an emeritus member of the Advisory Board for the Virginia Tech Program in Real Estate. He is a member of the Economic Club of Washington D.C. and has served on the Board of Directors for The First Tee.

Ward replaces Chandra Briggman, who resigned earlier this month after serving in the role since May 2020.

 

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation